Chronic High-Fat Diet Induces Early Barrett's Esophagus in Mice through Lipidome Remodeling

Biomolecules. 2020 May 16;10(5):776. doi: 10.3390/biom10050776.

Abstract

Esophageal adenocarcinoma (EAC) incidence has been rapidly increasing, potentially associated with the prevalence of the risk factors gastroesophageal reflux disease (GERD), obesity, high-fat diet (HFD), and the precursor condition Barrett's esophagus (BE). EAC development occurs over several years, with stepwise changes of the squamous esophageal epithelium, through cardiac metaplasia, to BE, and then EAC. To establish the roles of GERD and HFD in initiating BE, we developed a dietary intervention model in C57/BL6 mice using experimental HFD and GERD (0.2% deoxycholic acid, DCA, in drinking water), and then analyzed the gastroesophageal junction tissue lipidome and microbiome to reveal potential mechanisms. Chronic (9 months) HFD alone induced esophageal inflammation and metaplasia, the first steps in BE/EAC pathogenesis. While 0.2% deoxycholic acid (DCA) alone had no effect on esophageal morphology, it synergized with HFD to increase inflammation severity and metaplasia length, potentially via increased microbiome diversity. Furthermore, we identify a tissue lipid signature for inflammation and metaplasia, which is characterized by elevated very-long-chain ceramides and reduced lysophospholipids. In summary, we report a non-transgenic mouse model, and a tissue lipid signature for early BE. Validation of the lipid signature in human patient cohorts could pave the way for specific dietary strategies to reduce the risk of BE in high-risk individuals.

Keywords: Barrett’s esophagus; cardiac metaplasia; esophageal adenocarcinoma; lipid; lipidomics; microbiota.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / etiology*
  • Adenocarcinoma / metabolism
  • Animals
  • Barrett Esophagus / etiology*
  • Barrett Esophagus / metabolism
  • Barrett Esophagus / pathology
  • Deoxycholic Acid / toxicity
  • Diet, High-Fat / adverse effects*
  • Disease Models, Animal*
  • Esophageal Mucosa / metabolism
  • Esophageal Mucosa / pathology
  • Esophageal Neoplasms / etiology*
  • Esophageal Neoplasms / metabolism
  • Esophageal Neoplasms / pathology
  • Gastric Mucosa / metabolism
  • Gastric Mucosa / pathology
  • Gastrointestinal Microbiome
  • Lipid Metabolism*
  • Male
  • Mice
  • Mice, Inbred C57BL

Substances

  • Deoxycholic Acid